Zurich Cantonal Bank
CTKB icon

Zurich Cantonal Bank’s Cytek Biosciences CTKB Stock Holding History

Zurich Cantonal Bank’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,701
Closed -$70.4K – 2565
2025
Q2 		$70.4K Hold
20,701
– – ﹤0.01% 2427
2025
Q1 		$83K Hold
20,701
– – ﹤0.01% 2444
2024
Q4 		$134K Hold
20,701
– – ﹤0.01% 2326
2024
Q3 		$115K Hold
20,701
– – ﹤0.01% 2374
2024
Q2 		$116K Hold
20,701
– – ﹤0.01% 2319
2024
Q1 		$139K Hold
20,701
– – ﹤0.01% 2244
2023
Q4 		$189K Buy
20,701
+11,734
+131% +$73.9K ﹤0.01% 2114
2023
Q3 		$49.5K Hold
8,967
– – ﹤0.01% 2601
2023
Q2 		$76.6K Hold
8,967
– – ﹤0.01% 2462
2023
Q1 		$82.4K Hold
8,967
– – ﹤0.01% 2392
2022
Q4 		$91.6K Hold
8,967
– – ﹤0.01% 2325
2022
Q3 		$132K Hold
8,967
– – ﹤0.01% 2008
2022
Q2 		$96K Buy
+8,967
New +$89.2K ﹤0.01% 2274

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zurich Cantonal Bank's CTKB Position: Q3 2025 in Review

Zurich Cantonal Bank sold out of Cytek Biosciences (CTKB) in Q3 2025, closing a stake of 20,701 shares — an estimated $70.4K sold.

Zurich Cantonal Bank first reported a position in CTKB in Q2 2022 and held it in 13 quarters. The position peaked at $189K in Q4 2023. 153 funds tracked by Wall St. Rank hold CTKB as of Q3 2025.

  • Zurich Cantonal Bank reported no remaining Cytek Biosciences position as of Q3 2025 after selling out during the quarter.
  • Zurich Cantonal Bank sold 20,701 Cytek Biosciences shares in Q3 2025, an estimated $70.4K.
  • Zurich Cantonal Bank first reported a position in Cytek Biosciences in Q2 2022 and held it in 13 quarters.
  • Zurich Cantonal Bank's Cytek Biosciences position peaked at $189K in Q4 2023.
  • 153 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2025.

Based on Zurich Cantonal Bank's 13F filing for Q3 2025, filed 14 Nov 2025.